Pomerantz LLP is investigating Concentrix Corporation and its executives for potential securities fraud following the company's lowered revenue and earnings forecasts and a significant $1.05 billion goodwill impairment. Concentrix's stock price dropped sharply after these announcements, raising concerns among investors. The investigation aims to determine if the company engaged in unlawful business practices. Investors affected by these developments may consider joining the class action lawsuit being pursued by Pomerantz LLP.
Concentrix Corporation is the subject of an investor investigation. For readers following the Technology sector, here is Pluang's market snapshot as of Oct 28, 2026 04:01 WIB: of 150 priced US stocks, 80 rose and 70 fell. Notable movers include APLD at USD 19.50 (+9.37%), RGTI at USD 12.41 (+8.48%), and IREN at USD 27.41 (+7.79%).
The global drone defense system market is projected to grow from $4.72 billion in 2025 to $18.19 billion by 2030, driven by increasing unauthorized drone incidents and demand for advanced detection and countermeasure technologies. Growth is fueled by...
Nokia Oyj is rated Buy due to strong demand in its Optical and IP Networks segments, driven by previous design wins and new contracts with hyperscalers. The company expects 25%-30% growth in these areas by 2027, supported by margin improvements from ...
Icahn Enterprises L.P. announced it will present its third quarter 2026 financial results via a webcast on November 3, 2026, at 10:00 a.m. Eastern Time. The company operates across seven main sectors including Investment, Energy, Automotive, Food Pac...
Pomerantz LLP is investigating Omeros Corporation for potential securities fraud following two significant stock price drops after the European Medicines Agency (EMA) issued negative opinions on Omeros's drug narsoplimab for treating TA-TMA. The stoc...
Eli Lilly has outpaced Novo Nordisk in the GLP-1, obesity, and Type 2 Diabetes market, achieving a $1.21 trillion valuation. While Novo Nordisk's share price has fallen back after earlier gains and revenue growth remains flat, its management's strate...
